1. Signaling Pathways
  2. Epigenetics
  3. Histone Methyltransferase
  4. EZH2 Isoform

EZH2

 

EZH2 Related Products (24):

Cat. No. Product Name Effect Purity
  • HY-13470
    GSK126
    Inhibitor 99.98%
    GSK126 (GSK2816126A) is a potent, highly selective inhibitor of EZH2 methyltransferase with an IC50 of 9.9 nM.
  • HY-133129
    MS1943
    Inhibitor 98.02%
    MS1943 is a first-in-class, orally bioavailable EZH2 selective degrader, with an IC50 of 120 nM.
  • HY-15555
    EPZ005687
    Inhibitor 99.79%
    EPZ005687 is a potent and selective inhibitor of EZH2 with Ki of 24 nM, and has 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.
  • HY-103682
    PF-06726304
    Inhibitor 99.64%
    PF-06726304 is a potent and selective EZH2 inhibitor.
  • HY-12856
    GSK503
    Inhibitor 99.73%
    GSK503 is a potent and specific inhibitor of EZH2 methyltransferase with Kiapp values of 3 to 27 nM.
  • HY-147525
    PROTAC EZH2 Degrader-1
    Inhibitor 98.55%
    PROTAC EZH2 Degrader-1 (Compound 150d), a potent PROTAC EZH2 Degrader, exerts inhibitory effect on EZH2 methyltransferase activity with the IC50 of 2.7 nM.
  • HY-12186G
    3-Deazaneplanocin A hydrochloride (GMP)
    Inhibitor
    3-Deazaneplanocin A (DZNep) hydrochloride (GMP) is 3-Deazaneplanocin A hydrochloride (HY-12186) produced by using GMP guidelines.
  • HY-148333
    MS177
    Inhibitor
    MS177 is an effective and fast-acting EZH2 degrader.
  • HY-15573
    EI1
    Inhibitor 99.18%
    EI1 (KB-145943) is a potent and selective EZH2 inhibitor with IC50 of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.
  • HY-101508
    GNA002
    Inhibitor 98.05%
    GNA002 is a highly potent, specific and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor with an IC50 of 1.1 μM.
  • HY-N5024
    Gambogenic acid
    Inhibitor 99.91%
    Gambogenic acid is an active ingredient in gamboge, with anticancer activity.
  • HY-119198
    NSC745885
    Inhibitor ≥98.0%
    NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells.
  • HY-A0298
    EZH2-IN-2
    Inhibitor 98.06%
    EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC50 of 64 nM.
  • HY-16986A
    EPZ011989 trifluoroacetate
    Inhibitor 98.71%
    EPZ-011989 trifluoroacetate is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor with metabolic stability.
  • HY-144882
    (R)-HH2853
    Inhibitor
    (R)-HH2853 is a mutant EZH2 inhibitor with an IC50 of <100 nM for EZH2-Y641F.
  • HY-144881
    (S)-HH2853
    Inhibitor
    (S)-HH2853 (compound 200), a PYRIDINO five membered aromatic ring compound, is a potent EZH1/2 dual inhibitor with an IC50 of <100 nM for EZH2_Y641F.
  • HY-144905
    MC4355
    Inhibitor ≥98.0%
    MC4355 is a dual inhibitor of EZH2 and histone deacetylase (HDAC).
  • HY-103682A
    PF-06726304 acetate
    Inhibitor
    PF-06726304 acetate is a potent and selective EZH2 inhibitor.
  • HY-136188
    UNC2399
    Inhibitor
    UNC2399, a biotinylated UNC1999, is a selective EZH2 degrader, maintaining high in vitro potency for EZH2, with an IC50 of 17 nM.
  • HY-139150
    EZH2-IN-4
    Inhibitor
    EZH2-IN-4 is an orally active, potent EZH2 inhibitor with IC50s of 0.923 nM and 2.65 nM against wild type (WT) 5-membered (5-mer) EZH2 and mutant 5-mer EZH2, respectively.